The Methodist Medical Center of Illinois is a comprehensive service hospital whose aims and accomplishments are consistent with the CCOP program. Through physician leadership in its Medical and Radiation Oncology Centers, advances in oncological medical science have been brought to the community level. As a result, patients can receive sophisticated medical care right where they live. This transfer and delivery of the most current cancer treatment methodologies through community oncologists and other participating physicians are important ongoing activities. Treatment protocol participation on the part of involved oncologists facilitates this effort as well as providing valuable input to the clinical research trials. The Medical Center's own cancer control and other related programs and services support the multidisciplinary professional team of medical oncologists, radiation oncologists, pathologists, and surgeons, primary care physicians and oncology nurses and technologists. The Methodist Medical Center CCOP application objectives are as follows: (1) Bring the advantages of clinical research and most current cancer treatment methodologies to cancer patients in Central Illinois(2) Reduce cancer mortality in this region by a widespread community application of these methodologies. (3) Participate in nationally approved clinical research protocols including the entry of up to 300 patients per annum into the protocols provided by established research bases. (4) Provide educational and consultative services for community physicians to facilitate the transfer of medical advances to patterns of practice. (5) Serve as a resource for implementing other cancer control and prevention research initiatives of the National Cancer Institute. These objectives would be accomplished through already existing physician leadership and Medical Center support and relationships with the Mayo Clinic as a primary research base using the medium of the North Central Cancer Treatment Group along with a secondary research base relationship with the Eastern Cooperative Oncology Group and the Radiation Therapy Oncology Group (current participation with these research groups demonstrates the established high quality clinical research and treatment potential in a community setting of the Methodist Medical Cancer CCOP organization). CCOP funding and involvement will insure that this research and cancer control excellence can be maintained and expanded.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035113-03
Application #
3557507
Study Section
(SRC)
Project Start
1983-09-01
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Methodist Medical Center of Illinois
Department
Type
DUNS #
City
Peoria
State
IL
Country
United States
Zip Code
61636
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Zhao, Yujie; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10:172-80
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26

Showing the most recent 10 out of 165 publications